Loading…
H.R. 8205119th CongressPassed one chamberLatest action Jul 23, 2026Decoded by AI · checked against the record
Official title: Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Introduced:
Read the official bill on Congress.govThe plain-language version leads. The official text is always the reference.
HR 8205 extends ALS research grant funding authority from 2026 to 2031 and adds FDA oversight steps.
45-second read · 4 questions answered below
This bill extends the Accelerating Access to Critical Therapies for ALS Act, pushing its expiration from 2026 to 2031 so grant programs for ALS research can continue. It adds requirements for the FDA to check clinical trial progress, including interim data, when companies renew grants, and clarifies that "phase 3" trials include combined phase 2/3 and planned-but-not-yet-enrolling trials. It also requires an updated FDA action plan within a year and a GAO review within four years.
The bill affects ALS patients and families, pharmaceutical and biotech companies developing ALS treatments, and researchers using federal grants. The FDA gains added reporting and oversight duties.
The extension keeps existing grant funding authority active rather than letting it lapse in 2026, while adding new FDA data-sharing and reporting requirements that increase oversight of grant recipients.
AI-drafted summary. Verify it against the official text before you act on it. Read the official bill on Congress.gov
Right now: it passed the House, and the official record shows nothing new since. If the Senate changes it, it goes back to the House before reaching the President.
Latest action: — Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.